Login to Your Account



Adolor's Stock Suffers After Last Entereg Phase III Fails

By Kim Coghill


Thursday, January 15, 2004
Despite mediocre results from their fourth Phase III trial, Adolor Corp. and partner GlaxoSmithKline plc expect to seek regulatory approval this year for Entereg in the management of postoperative ileus. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription